Recent developments include updates on FDA application study results, earnings increase, successful warrant offering, and ongoing commercial activities with Chinese distributors and new partners.

• Guided Therapeutics provided updates on FDA application study results, 2025 earnings increase, and successful warrant offering as of March 31, 2026 [N8].
• The company has received payments from Chinese distributors as part of a $700,000 purchase order, including an $88,000 third installment payment in December 2025 [N8].
• Guided Therapeutics inked a $200,000 deal with new distribution partner Yuanshuo Medical Instruments Corporation in November 2025 [N8].
• The company received $70,000 as the second of nine payments totaling $700,000 from a new Chinese distribution partner in August 2025 [N8].
• Guided Therapeutics announced completion of the US FDA clinical trial in August 2025, with patient enrollment and data analysis completed [N8].

The company's LuViva device addresses significant clinical needs by providing a non-invasive, painless cervical cancer detection method with rapid results, potentially improving patient well-being and reducing unnecessary follow-up procedures. Regulatory progress includes completed clinical trials for FDA approval and ongoing applications in China and other international markets. The company has secured purchase orders and payments from distributors in multiple countries, indicating initial market acceptance. Strategic collaborations and government-funded clinical studies, such as in Turkey, may support broader adoption. The company's focus on cervical cancer detection aligns with global health priorities, and its proprietary technology may offer competitive advantages.

Guided Therapeutics faces substantial risks including its history of operating losses and accumulated deficit, limited manufacturing and marketing experience, and dependence on obtaining regulatory approvals which remain uncertain in timing and outcome. The company's liquidity is constrained with a working capital deficit and significant convertible debt in default, which may hinder its ability to raise additional funds on acceptable terms. Market acceptance of LuViva is unproven with limited sales history and contingent on regulatory clearances. Geopolitical risks, including the Russia-Ukraine conflict and international trade uncertainties, may disrupt operations and supply chains. Failure to secure sufficient funding or regulatory approvals could impair the company's ability to continue operations or commercialize its products effectively.

Guided Therapeutics' moat is based on its proprietary biophotonics technology embodied in the LuViva device, which offers a non-invasive, painless, and rapid cervical cancer detection alternative. The device's dual application in both developing and developed markets addresses unmet needs in cervical cancer screening and triage. The company's regulatory progress, including clinical trials and certifications such as ISO 13485:2016 and CE Mark, supports its market entry barriers. However, the moat is challenged by the company's limited manufacturing and marketing experience, regulatory uncertainties, and competitive pressures in the medical device industry.

• Funding and Going Concern Risk: The company requires additional capital to fund operations, complete regulatory approvals, and scale manufacturing. There is substantial doubt about its ability to continue as a going concern due to recurring losses and working capital deficits.
• Regulatory Approval Uncertainty: Obtaining FDA clearance and international regulatory approvals is uncertain and may involve delays, additional studies, or failure to obtain approval, limiting the ability to market products.
• Limited Commercial Experience: The company has limited experience in manufacturing, marketing, and selling its products, which may impact its ability to grow sales and achieve profitability.
• Geopolitical and International Risks: Operations are subject to risks from geopolitical conflicts, trade restrictions, currency fluctuations, and compliance with anti-corruption laws, which may adversely affect business and financial condition.
• Competitive and Industry Risks: The medical device industry is highly competitive with a high failure rate for new entrants, and the company faces risks from competition and rapid technological changes.

• Guided Therapeutics Inc is a medical technology company focused on developing and marketing the LuViva® Advanced Cervical Scan, a non-invasive cervical cancer detection device using biophotonics technology to scan the cervix with light and analyze reflected and fluorescent light for cancer and precancer detection.
• LuViva provides a less invasive, painless alternative to conventional cervical cancer screening tests, offering rapid results at the point of care.
• The company targets two primary applications for LuViva: as a cancer screening tool in developing countries with limited infrastructure, and as a triage tool following traditional screening in developed countries to reduce unnecessary follow-up tests.
• Guided Therapeutics was originally incorporated in 1992 as SpectRx, Inc., renamed in 2008 to Guided Therapeutics, Inc., and established a wholly owned subsidiary GTHP Turkey in 2026 with limited operations to date.
• The company has limited experience in manufacturing, marketing, and selling its products and has historically incurred operating losses since inception, with an accumulated deficit of approximately $158.7 million as of June 30, 2026.
• The company has generated limited revenues to date, primarily from sales of LuViva devices and disposables, with current demand based on purchase orders and discussions with customers and partners totaling approximately $1.0 million potential sales within the next twelve months, contingent on regulatory approvals.
• Guided Therapeutics is focused on three primary markets for LuViva: the United States, China, and Europe, with additional sales orders from Turkey and Indonesia where regulatory approvals have been obtained.
• The company has not yet obtained U.S. FDA clearance or approval but completed patient enrollment in the required clinical trial with approximately 480 patients enrolled and 428 evaluable for efficacy analysis, with no adverse events reported related to LuViva.
• The FDA application was filed in June 2026, and the company is awaiting FDA response; the FDA may require a manufacturing inspection and/or post-marketing study.
• In China, the company has filed for NMPA approval with the application accepted and under review since January 2025; manufacturing inspection is anticipated with potential approval timing uncertain.
• The company has distribution partners in China (HDMT and YMIC) who continue to place product orders; YMIC is approved by the Chinese government to manufacture Class III medical devices.
• Guided Therapeutics has obtained and maintained ISO 13485:2016 certification and the CE Mark through its contract manufacturer, Newmars Technologies, but the CE Mark maintenance is uncertain due to evolving standards.
• The company has received regulatory approval for LuViva in Russia and is focusing marketing efforts there despite complications from the Russia-Ukraine conflict.
• In Turkey, the company is in contract discussions with the Ministry of Health to conduct a clinical study for primary cervical cancer screening using LuViva, potentially involving significant annual testing volumes.
• In Indonesia, the company received an order and full payment for four LuViva devices and 1,200 disposables, with shipment delayed pending final payment for shipping and services.
• The company has a working capital deficit of approximately $5.6 million as of June 30, 2026, with cash and equivalents of approximately $731,000 as of September 30, 2023.
• The company reported a net loss of $605,000 for the quarter ended June 30, 2026, with basic and diluted EPS of -$0.01 per share.
• Liquidity ratios as of June 30, 2026, include a current ratio of 0.09 and a cash ratio of 0.12, indicating limited short-term liquidity.
• The company has outstanding convertible debt, including a $1.13 million senior unsecured convertible debenture in default, accruing interest at a default rate of 18%.
• The company has historically raised capital through public and private sales of debt and equity, collaborative arrangements, and grants.
• The company faces substantial risks including the need to raise additional funds to continue operations and complete regulatory approvals, the uncertainty of obtaining FDA and international regulatory clearances, and the challenges of manufacturing scale-up and market acceptance.
• The company operates in a highly competitive and rapidly changing medical device industry with a high failure rate for new entrants.
• The ongoing geopolitical conflicts, including the Russia-Ukraine war and tensions in the Middle East, may adversely affect the company's operations and supply chains.
• The company is subject to extensive government regulation in the U.S., Europe, China, and other markets, which can cause delays and increased costs in product commercialization.
• The company has limited operating history in sales and marketing and may not be successful in growing sales or achieving profitability.
• The company has implemented operating cost reductions and focuses on cervical cancer detection as its primary business.
• The company has received recent payments from Chinese distributors as part of purchase orders and has ongoing discussions with new distribution partners.
• The company has a history of recurring losses and expects operating losses to continue as it advances regulatory and commercialization efforts.